DueDiligence
ExploreSearchAbout
PODD·NasdaqGS·Healthcare

Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

$146.89
↓1.25(0.84%)
Market cap $10.2B
Revenue
$2.7B
↑ 30.7% YoY
Net Income
$247.1M
↓ 40.9% YoY
Gross Profit
—

Generating analysis for Insulet Corporation… this takes ~10 seconds the first time.

Compare
Related companies
DXCMDexcomABTAbbottMDTMedtronic

Deep Dive

Member

A full investor briefing on Insulet Corporation — history, leadership, risks, and outlook.